Adma Biologics (ADMA) Cash from Operations Growth (5y) (2016 - 2025)
Adma Biologics (ADMA) Cash from Operations Growth (5y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Adma Biologics | 2.03 Bn | 1.94 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.44% |
| Sep 30, 2025 | 20.66% |
| Jun 30, 2025 | 24.52% |
| Mar 31, 2025 | 4.41% |
| Dec 31, 2024 | 35.43% |
| Sep 30, 2024 | 25.06% |
| Jun 30, 2024 | 34.80% |
| Mar 31, 2024 | 31.10% |
| Dec 31, 2023 | 24.04% |
| Sep 30, 2023 | 24.20% |
| Jun 30, 2023 | 16.48% |
| Mar 31, 2023 | 2.17% |
| Dec 31, 2022 | 11.19% |
| Sep 30, 2022 | -6.41% |
| Jun 30, 2022 | -7.89% |
| Mar 31, 2022 | -36.96% |
| Dec 31, 2021 | -56.07% |
| Sep 30, 2021 | -23.42% |
| Jun 30, 2021 | -46.36% |
| Mar 31, 2021 | -45.09% |